U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)
(X) QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended August 31, 2008

OR

( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the transition period from _____ to _____.

Commission File Number 0-12305

REPRO-MED SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

New York	13-3044880
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

24 Carpenter Road, Chester New York	10918
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (845) 469-2042

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [X] Yes [ ] No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]	Accelerated filer [ ]
Non-accelerated filer [ ]	Smaller reporting company [X]

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [ ] Yes [X] No

As of August 31, 2008, 34,829,286 shares of common stock, $.01 par value per share, were outstanding.

REPRO-MED SYSTEMS, INC.
TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION PAGE

ITEM 1. Financial Statements

PART I - FINANCIAL INFORMATION

ITEM 1. Financial Statements

REPRO-MED SYSTEMS, INC.
BALANCE SHEETS

	AUGUST 31, 2008 (UNAUDITED)	FEBRUARY 29, 2008
ASSETS		
CURRENT ASSETS:		
Cash	$ 151,854	$ 95,561
Accounts receivable less allowance for doubtful accounts of $25,985 and $26,115 at August 31, 2008 and February 29, 2008, respectively	411,254	297,206
Inventory	563,773	551,032
Prepaid expenses	76,050	44,392
Total Current Assets	1,202,931	988,191
PROPERTY & EQUIPMENT, less accumulated depreciation of $1,161,055 and $1,126,612 at August 31, 2008 and February 29, 2008 respectively	201,234	235,677
OTHER ASSETS:		
Patents, net of accumulated amortization of $88,743 and $82,590 at August 31, 2008 and February 29, 2008, respectively	38,365	44,354
Goodwill	8,609	8,609
Security deposit	28,156	28,156
Total Other Assets	75,130	81,119
TOTAL ASSETS	$ 1,479,295	$ 1,304,987
LIABILITIES AND STOCKHOLDERS' (DEFICIT)		
CURRENT LIABILITIES		

Note payable to financial institution	$ 394,267	$ 400,000
Note payable - current portion	4,377	4,293
Notes payable to related parties - current portion	15,000	15,000
Deferred capital gain - current portion	22,481	22,481
Accounts payable	148,676	342,433
Accrued expenses	71,179	53,180
Accrued interest	68,190	63,590
Accrued preferred stock dividends	56,000	52,000
Accrued payroll and related taxes	11,041	18,594
Warranty liability	62,194	62,194
Customer Deposits	-	5,180
Total Current Liabilities	853,405	1,038,945
OTHER LIABILITIES		
Note payable - less current portion	30,142	32,250
Notes payable to related parties - less current portion	394,000	394,000
Deferred capital gain less current portion	213,575	224,815
Total Other Liabilities	637,717	651,065
Total Liabilities	1,491,122	1,690,010
STOCKHOLDERS' DEFICIT		
Preferred Stock, 8% cumulative, liquidation value $100,000, $0.01 par value, 2,000,000 shares authorized, 10,000 shares issued and outstanding at August 31, 2008 and February 29, 2008	100	100
Common Stock, $0.01 par value, 50,000,000 shares authorized, 34,829,286 issued and outstanding at August 31, 2008 and February 29, 2008	348,293	348,293
Additional paid-in Capital	2,879,123	2,846,094
Accumulated deficit	(3,097,343)	(3,437,510)
	130,173	(243,023)
Less: Treasury Stock, 2,275,000 shares at cost at August 31, 2008 and February 29, 2008	(142,000)	(142,000)
Total Stockholders' Deficit	(11,827)	(385,023)
Total Liabilities and Stockholders' Deficit	$ 1,479,295	$ 1,304,987

See Accompanying Notes to Financial Statements

</TABLE>
<TABLE>

REPRO-MED SYSTEMS, INC.
STATEMENTS OF OPERATIONS (UNAUDITED)

<CAPTION>

	FOR THE THREE MONTHS ENDED AUGUST 31		FOR THE SIX MONTHS ENDED AUGUST 31	
	2008	2007	2008	2007
<S>	<C>	<C>	<C>	<C>
NET SALES	$ 936,495	$ 605,946	$ 1,636,471	$ 1,003,364
COST AND EXPENSES				
Cost of goods sold	317,815	189,827	608,935	389,433
Selling, general and administrative	291,729	317,956	602,882	579,461
Research and development	6,728	12,358	10,033	26,111
Depreciation and amortization	22,440	16,001	40,596	32,062
TOTAL COSTS AND EXPENSES	638,712	536,142	1,262,446	1,027,067
NET OPERATING INCOME (LOSS)	297,783	69,804	374,025	(23,703)
OTHER INCOME/(EXPENSES)				
Interest Expense	(18,262)	(15,437)	(29,866)	(100,962)
Interest and Other Income	8	-	8	512

TOTAL OTHER INCOME/(EXPENSE)	(18,254)	(15,437)	(29,858)	(100,450)
INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES .	279,529	54,367	344,167	(124,153)
Provision for Income Taxes	-	-	-	-
NET INCOME (LOSS)	279,529	54,367	344,167	(124,153)
PREFERRED STOCK DIVIDENDS	4,000	4,000	4,000	4,000
NET INCOME (LOSS) AVAILABLE TO COMMON STOCKHOLDERS	$ 275,529	$ 50,367	$ 340,167	$ (128,153)
NET INCOME (LOSS) PER COMMON SHARE AVAILABLE TO COMMON STOCKHOLDERS	$ 0.01	$ 0.01	$ 0.01	$ (0.01)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING ...	34,829,286	-	34,829,286	31,903,275

See Accompanying Notes to Financial Statements

</TABLE>
<TABLE>

REPRO-MED SYSTEMS, INC.
STATEMENTS OF CASH FLOWS (UNAUDITED)

<CAPTION>

	FOR THE SIX MONTHS ENDED	
	AUGUST 31, 2008	AUGUST 31, 2007
<S>	<C>	<C>
CASH FLOWS FROM OPERATING ACTIVITIES		
Net Income (Loss)	$ 344,167	$(124,153)
Adjustments to reconcile net income (loss) to net cash from operating activities:		
Stock based Compensation	24,209	71,090
Interest charged to additional paid in capital	8,820	-
Depreciation and amortization	40,596	32,062
Deferred capital gain - building lease	(11,240)	(11,240)
Changes in operating assets and liabilities:		
(Increase) decrease in accounts receivable	(114,048)	(38,047)
(Increase) decrease in inventory	(12,741)	(23,316)
(Increase) decrease in prepaid expenses	(31,658)	(15,566)
(Increase) decrease in security deposits	-	26,646
Increase (decrease) in accounts payable	(193,757)	37,214
Increase (decrease) in accrued payroll and related taxes	(7,553)	2,948
Increase (decrease) in accrued expenses	17,999	24,860
Increase (decrease) in accrued preferred stock dividends	4,000	4,000
Increase (decrease) in customer deposits	(5,180)	-
Increase (decrease) in accrued interest	4,600	4,342
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	68,214	(9,160)
CASH FLOWS FROM INVESTING ACTIVITIES		
Payments for property and equipment	-	(6,100)
Reduction in patents	516	-
Payments for patents	(680)	(6,260)
NET CASH USED IN INVESTING ACTIVITIES	(164)	(12,360)
CASH FLOWS FROM FINANCING ACTIVITIES		
Net payments on note payable to financial institution	(5,733)	-
Proceeds from note payable to related parties	-	(3,238)
Payments on notes payable	(2,024)	-
Payments on capitalized lease obligations	-	(617)
Preferred stock dividends	(4,000)	(4,000)

NET CASH USED IN FINANCING ACTIVITIES	(11,757)	(7,855)
NET INCREASE (DECREASE) IN CASH	56,293	(29,375)
CASH BEGINNING OF YEAR	95,561	99,421
CASH END OF YEAR	$ 151,854	$ 70,046
Supplemental Information		
Cash paid during the year for:		
Interest	$ 8,209	$ 13,187

See Accompanying Notes to Financial Statements

</TABLE>

REPRO-MED SYSTEMS, INC.
NOTES TO FINANCIAL STATEMENTS

BASIS OF PRESENTATION
- ---

The accompanying unaudited financial statements as of August 31, 2008 and for the three month and six month periods ended August 31, 2008, have been prepared in accordance with generally accepted accounting principles in accordance with instructions to regulation S-X. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial presentation. In the opinion of the Company's management, the financial statements contain all adjustments (consisting of normal recurring accruals) necessary to present fairly the Company's financial position as of August 31, 2008 and the results of operations and cash flows for the interim periods ended August 31, 2008 and 2007.

The results of operations for the six-month period ended August 31, 2008, are not necessarily indicative of the results to be expected for the year ending February 28, 2009. These interim financial statements should be read in conjunction with the financial statements and notes thereto of the Company and management's discussion and analysis of financial condition and results of operations included in the Company's Annual Report for the year ended February 29, 2008, as filed with the Securities and Exchange Commission on Form 10-KSB.

INVENTORY
- ---

Inventory consist of the following:

	August 31, 2008 (Unaudited)	February 29, 2008
Raw materials	$ 455,634	$ 426,587
Work in progress	56,992	56,992
Finished goods	51,147	67,453
	$ 563,773	$ 551,032

STOCKHOLDERS' EQUITY/NOTES PAYABLE TO RELATED PARTIES
- ---

During the three month and six month periods ended August 31, 2008, $4,410 and $8,820,respectively of interest accruing on a note payable to related party was charged to additional paid-in capital.

RECLASSIFICATIONS
- ---

Certain amounts in the February 29, 2008 and August 31, 2007, financial

statements have been reclassified to conform to the presentation used in the August 31, 2008, financial statements.

PART I ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Quarterly Report on Form 10-Q contains certain "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995) and information relating to us that are based on the beliefs of the management, as well as assumptions made by and information currently available. Our actual results may vary materially from the forward-looking statements made in this report due to important factors such as, recent operating losses, uncertainties associated with future operating results, unpredictability related to Food and Drug Administration regulations, introduction of competitive products, limited liquidity, reimbursement related risks, government regulation of the home health care industry, success of the research and development effort, market acceptance of Freedom60(R), availability of sufficient capital to continue operations and dependence on key personnel. When used in this report, the words "estimate," "project," "believe," "anticipate," "intend," "expect" and similar expressions are intended to identify forward-looking statements. Such statements reflect current views with respect to future events based on currently available information and are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. These statements involve risks and uncertainties with respect to the ability to raise capital to develop and market new products, acceptance in the market place of new and existing products, ability to penetrate new markets, our success in enforcing and obtaining patents, obtaining required Government approvals and attracting and maintaining key personnel that could cause the actual results to differ materially. Repro-Med does not undertake any obligation to release publicly any revision to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

THREE MONTHS ENDED AUGUST 31, 2008 VS. 2007

Led by strong sales of our Freedom60 line and increasing sales of the RES-Q-VAC(R), our net profit for the Quarter ending August 31, 2008 was $279,529 (which contains stock based compensation of $24,209) as compared to $54,367 (which included stock based compensation of $2,250) for the same quarter in 2007, an increase of 414%. Selling, General and Administrative Expense (SG&A) decreased $26,227 from $317,956 to $291,729 quarter over quarter 2007 vs. 2008, due to a legal agreement and fees associated with a mediation agreement in the prior year's quarter. Product liability insurance increased slightly by $871 to $6,512. Research and Development decreased to $6,728 from $12,358 primarily due to reallocation of resources from engineering to sales.

Total sales increased by 55% ($330,549) from $605,946 to $936,495 for the three-month period ending August 31, 2008 as compared to the previous quarter ending August 31, 2007.

Sales of the Freedom60 Syringe Infusion System, related accessories and repairs increased overall by 86% in the second quarter ending August 31, 2008 as compared to the same period in 2007. This increase is due to the increased sales for use with immune globulin caused by Medicare specifying the Freedom60 for use with SCIG, and antibiotics along with word of our performance and costs being communicated throughout the industry. Sales of RES-Q-VAC and related accessories showed an overall increase of 30% from $244,756 to $318,983 which includes a domestic increase of 60% and an international increase of 12%. Company sales of non-core Gyneco, Restore, and OEM products line decreased slightly by 9% for the period August 31, 2008 over August 31, 2007.

Interest expense increased by $2,825 to $18,262 from $15,437 as a result of recording stock based compensation of $8,237 which was partially offset by the Company paying off high interest on demand bank notes and capital leases.

SIX MONTHS ENDED AUGUST 31, 2008 VS. 2007
- ----------

Net Income shows a profit of $344,167 for the six-months ending August 31, 2008 as compared to a loss of $124,153 for the same six months in 2007 and represents a total improvement of $468,320.

Total sales increased by 63% ($633,107) to $1,636,471 from $1,003,364 for the six-month period ending August 31, 2008.

Sales of the Freedom60 Syringe Infusion System, related accessories and repairs increased 104% in the six-months ended August 31, 2008 vs. six-months ended August 31, 2007. We have concentrated the majority of our efforts in the Freedom60 line, specifically towards the subcutaneous immune globulin (SCIG) market. This sales increase was due to our direct efforts, and the reimbursement which was increased twenty fold and subsequently resulted in Medicare issuing a letter of clarification stating the Freedom60 as the only pump approved for SCIG reimbursement. Lastly, we diligently called on, in-serviced and sold virtually every major SCIG provider in the domestic market. We anticipate these sales to continue to increase as the SCIG market continues to develop and as we work on new enhancements to the Freedom60 that we believe will expand this market even further. In addition, many of the SCIG users will see benefit in using the Freedom60 system for other uses, such as antibiotics, chemotherapeutics and pain medications. Sales of the RES-Q-VAC increased overall by 34% with the international sales increasing by 31.4% offset by the domestic decreasing by 37% for the six-months ended August 31,2008 vs. six-months ended August 31, 2007.

Selling, General and Administrative Expense (SG&A) increased 4.0% to $602,882 in 2008 from $579,461 in 2007. This increase is directly related to an increase in trade show expenses, and higher recruiting expenses associated with the hiring of additional staff.

Research and development expenses decreased $16,078 from 2007 to 2008.

Depreciation and amortization expense increased by $8,534 from 2007 to 2008 as a result of new depreciation on capital equipment and adjustments to certain patent expenses. Interest expense for the six months has decreased $85,525 from 2007 to 2008 as a result of paying off high interest notes to the bank.

LIQUIDITY AND CAPITAL RESOURCES
- ----------

Net profit for the quarter ended August 31, 2008 improved to $279,529 (which contains stock based compensation of $24,209) as compared to $54,367 (which included stock based compensation of $2,250) for the previous year's quarter primarily as a result of our improved sales performance, especially with our Freedom60.

For the six months ended August 31, 2008, the net profit increased to $344,167 (which contained stock based compensation of $24,209) as compared to the a loss of $124,153 for the six months of the previous year (which contains stock based compensation of $71,090) This profit was due to a significant increase in Freedom60 sales, and an increase in the RES-Q-VAC as well. For the six months ending August 31, 2008, Net Cash from Operations was $68,214 as compared with ($9,160) for the prior year. This increase is due primarily to increased sales and certain cost controls related to Selling and General and Administrative Expense.

In January of 2008 we were notified by The Trade Adjustment Assistance Program of the Trade Department that our application for a grant of $150,000 was approved for use to assist us with marketing, ISO and regulatory affairs, and new product development. The grant matches the company on a 50-50 basis thereby reducing our costs for these new programs in half. The Trade Adjustment Assistance Program is a United States Government program to help manufacturing firms adjust to foreign business competition. The program is authorized by the Trade Act of 1974 and is administered by the U. S. Department of Commerce. The program operates through Trade Adjustment Assistance Centers located across the United States. The New York State area is served by the New York State Trade Adjustment Assistance Center (NYS TAAC). The NYS TAAC is affiliated with the Research Foundation of the State University of New York at Binghamton. Several payments were issued during this quarter pursuant to this program.

In raising capital beginning in February 2004, the Company issued promissory notes in the total amount of $432,000. These five-year promissory notes paid 2% over prime plus four shares of common stock per year for every year the loan was in place. The loans were fully satisfied by the end of February 2008 and replaced with a simple loan secured with an interest rate set at prime on February 21, 2008.

We believe the Freedom60 continues to find a solid following in the subcutaneous immune globulin market and this market is expected to continue to increase both domestically and internationally. We continue to experience an increase in sales and cash flow during six months ended August 31, 2008 and with these increases and the capital we currently have, we will continue to meet or exceed the company's financial goals. If the sales continue to increase at the current rate, which we feel confident of but cannot assure, we believe we will have sufficient resources to meet our financial obligations for the next twelve months from our cash flow alone.

FREEDOM60
- ---------

The Freedom60 Syringe Infusion Pump is designed for ambulatory medication infusions. Ambulatory infusion pumps are most prevalent in the home care market. Other potential applications for the Freedom60 are pain control, the infusion of specialized drugs such as IgG, and chemotherapy. The home infusion therapy market is comprised of approximately 4,500 sites of service, including local and national organizations, hospital-affiliated organizations, and national home infusion organizations, and produces approximately $4.5 Billion in revenue annually (Ref: www.nhianet.org). With insurance reimbursement in a severe decline, there is a tremendous need for a low-cost, effective alternative to electronic and expensive disposable IV administration devices for the home care. The Freedom60 provides a high-quality delivery to the patient at costs similar to gravity and is targeted for the home health care industry, patient emergency transportation, and for any time a low-cost infusion is required.

For the home care patient, Freedom60 is an easy-to-use lightweight mechanical pump using a 60cc syringe, completely portable, cost effective and maintenance free, with no batteries to replace and no cumbersome IV pole. For the infusion professional, Freedom60 delivers precise infusion rates and uniform flow profiles providing consistent transfer of medication. A Form 510(k) Pre-market Notification for initial design of the Freedom60 as a Class II device was approved by the FDA in August 1994.

The Company also designed and manufactured the Freedom60-FM, an enhanced version of the Freedom60 which contains an electronic flow monitor system that provides occlusion and end of infusion alarm. This product is directed at nursing homes, hospitals and pediatric ambulatory applications where alarms are generally required for nursing acceptance. Nurses also appreciate being able to visualize the drug volume by reading the scale on the syringe.

We have expanded the use of the Freedom60 to cover most antibiotics including the widely used and somewhat difficult to administer vancomycin. We have also found a following for Freedom60 for use in treating thalissemia with the drug desferal. In Europe we found success in using the Freedom60 for pain control, specifically post-operative epidural pain administration. Our European market also uses the Freedom60 for chemotherapy.

The Freedom60 use for Primary Immune Deficiency by injecting immune globulin (IgG) under the skin as a subcutaneous administration has seen increased usage over the past year. This method has provided patients with vastly improved quality of life with much fewer unpleasant side effects over the traditional intravenous route. The Freedom60 is an ideal system for this administration since the patient is able to self-medicate at home, the pump is easily configured for this application, and the Freedom60 is the lowest cost infusion system available in a heavily cost constrained market. We have begun to advertise one of the main benefits of the Freedom60 for use with IgG which is that it operates in "dynamic equilibrium"; that is the pump finds and maintains a balance between what a patient is able to absorb and what the pump infuses. This balance is created by a safe, limited and controlled pressure which adjusts the flow rate automatically to the patient's needs providing a reliable, faster and a more comfortable administration with fewer side effects for these

patients.

Repro-Med Systems' objective is to build a product franchise with Freedom60 and the sale of patented disposable tubing sets. Freedom60 uses rate-controlled tubing with standard slide clamp and luer-lock connector on the patient end. Our patented syringe disc connector insures that only the Company's Freedom60 tubing sets will function with the pump. Non-conforming tubing sets, without the patented disc connector, are ejected from the pump to prevent the danger of an overdose or runaway pump from injuring the patient.

THE MARKET FOR INFUSION PUMPS & DISPOSABLES
- ----------

The ambulatory infusion market has been rapidly changing due to reimbursement issues. Insurance reimbursement has drastically reduced the market share of high-end electronic type delivery systems as well as high-cost disposable non-electric devices, providing an opportunity for the Freedom60. We believe market pressures have moved to consider alternatives to expensive electronic systems especially for new subcutaneous administrations which usually cannot be done with gravity. For cost concerns some patients have been trained to administer intravenous drugs through IV push where the drug is pushed into the vein directly from a syringe. This is a low-cost option but has been associated with complications and considered by many to be a high-risk procedure. Thus, the overall trend has been towards syringe pumps due to the low-cost of disposables.

In order to receive more favorable Medicare reimbursement for our Freedom60 Syringe Infusion System, we had submitted a formal request for a HCPCS coding verification with the Statistical Analysis Durable Medical Equipment Regional Carrier (SADMERC). On May 21, 2007 we received a notification from CMS (Centers for Medicare & Medicaid Services) that the Freedom60 had been re-reviewed for Medicare billing. It was the determination that the Medicare HCPCS code(s) to bill the four Durable Medical Regional Carries (DMERCs) should be: E0779 Ambulatory infusion pump, mechanical, reusable, for infusion 8 hours or greater. The new coding provides for a substantial increase in reimbursement for providers using an infusion pump for authorized users under Part B of Medicare. Current approved uses under Medicare include among others, subcutaneous immune globulin, antivirals, antifungals, and chemotherapeutics. In June 2007 CMS issued a clarification that the Freedom60 Syringe Infusion Pump is the only allowable pump to be billed with subcutaneous immune globulin under HCPCS code E0779.

COMPETITION FOR THE FREEDOM60
- ----------

Competition for the Freedom60 for IgG is currently limited to electrically powered infusion devices which are more costly and can create high pressures during delivery which can cause complications for the administration of IgG. However, there can be no assurance that other companies with great resources will enter the market with competitive products which will have an adverse effect on our sales.

There is the potential for new drugs to enter the market, such as using Hyaluronidase which can facilitate absorption of IgG, making multiple site infusions unnecessary and changing the market conditions for devices such as the Freedom60. We believe the Freedom60 is ideal for all these new drug combinations but there can be no assurance that these newer drugs will have the same needs and requirements as the current drugs being used.

There can be no assurance that Medicare will continue to provide reimbursement for the Freedom60 or they may allow reimbursement for other infusion pumps that are currently in the market or new ones that may enter shortly, which could adversely affect our sales into this market.

RES-Q-VAC
- ---------

The RES-Q-VAC Emergency Airway Suction System is a lightweight, portable, hand-operated suction device that removes fluids from a patient's airway by attaching the RES-Q-VAC pump to various proprietary sterile and non-sterile single-use catheters sized for adult and pediatric suctioning. The one-hand operation makes it extremely effective and the product is generally found in

emergency vehicles, hospitals and wherever portable aspiration is a necessity, including backup support for powered suction systems. The disposable features of the RES-Q-VAC reduce the risk of contaminating the health professional from HIV or SARS when suctioning a patient or during post treatment cleanup. All of the parts that connect to the pump are disposable.

We recently introduced a new version of the RES-Q-VAC with the addition of a portable LED white light, which attaches to the canister assembly. The light is fully malleable and can direct light during operations when lighting is poor or at night. We have our latest version of the RES-Q-VAC called Ultra which contains all of our latest enhancements. We have begun marketing the RES-Q-VAC UTRA both domestically and with a distributor in Italy.

A critical component and advantage of the RES-Q-VAC ULTRA is the Full Stop Protection, (FSP) a recently patented filtering system that both prevents leakage and over-flow of the aspirated fluids, even at full capacity, and traps all air and fluid borne pathogens and potentially infectious materials within the sealable container. This protects users from potential exposure to disease and contamination. The Full Stop Protection meets the requirement of the Occupational Safety and Health Administration. The Company has received a letter from OSHA confirming that the RES-Q-VAC with the Full Stop Protection falls under the engineering controls of the Blood borne Pathogen regulation and that the Products use would fulfill the regulatory requirements.

We have also added new connectors to our pediatric catheters, which allow them to connect directly to the adult containers with FSP. These connectors allow pediatric suctioning with the benefit of the Full Stop Protection device as well as with sterile catheters. Many infants are born with contagious diseases and the new system eliminates this concern among paramedics during an emergency delivery.

A critical advantage of our RES-Q-VAC airway suction system is versatility. With the addition of Full Stop Protection, we created specific custom RES-Q-VAC kits for various vertical markets:

Emergency Medicine - we make several special kits for emergency use, which contain all the catheters necessary to treat adults as well as infants or children. These first responder kits are generally non-sterile. We also have special attachments available for the advanced paramedic to treat patients who are intubated.

Respiratory - in-home care, long term care, situations requiring frequent suctioning such as cystic fibrosis patients, patients with swallowing disorders, elderly, patients on ventilators and with tracheostomies all benefit from the portability, cost and performance of the RES-Q-VAC. In hospitals, the RES-Q-VAC provides emergency back up due to power loss or breakdown of the wall suction system.

Hospital Use - for crash carts, the emergency room, patients in isolation, moving patients throughout the hospital (e.g., from ICU to Radiology) and backup for respiratory, RES-Q-VAC is available sterile with Full Stop Protection for the ultimate in performance and to meet all the OSHA regulations and CDC guidelines for use in treating patients in isolation, and in any location. Hospitals are required under the EMTALA regulations to provide emergency treatments to patients anywhere in the primary facility and up to 250 yards away. The RES-Q-VAC insures full compliance with these regulations and helps minimize unfavorable outcomes and potential lawsuits there from. We provide special hospital kits, which are fully stocked to meet all hospital applications for both adult and pediatric.

Nursing Homes, Hospice, Sub-acute - we provide special configurations for dining areas, portable suctioning for outside events and travel. Chronic suction can be accommodated with RES-Q-VAC, which can be left by the bedside for rapid use during critical times.

Dental Applications - we offer a version of the RES-Q-VAC, called DENTAL-EVAC which addresses the needs of oral surgeons for emergency back up suction during a procedure. DENTAL-EVAC is supplied with the dental suction attachments such as saliva ejector and high volume evacuator.

Military Applications - due to its lightweight, portability, and rapid

deployment, we believe that the RES-Q-VAC is ideal for any military situation. In addition, rapid, aggressive, and repeated suctioning best treats exposure to chemical weapons of mass destruction such as Sarin. We believe that the RES-Q-VAC's compact size, powerful pump, and full protection of the user from any contamination, gives us a competitive edge in this market.

RES-Q-VAC is sold domestically and internationally by emergency medical device distributors. These distributors generally sell to the end user and advertise these products in relevant publications and in their catalogs.

COMPETITION FOR THE RES-Q-VAC
- ----------

Currently there are a number of competitive devices built in China such as Ambu Res Cue Pump and Easy Breezer, which are essentially copies of the RES-Q-VAC technology, and are available at lower costs. There is also a device called V-Vac made by Laerdal which has strong representation. None of these devices have our patented Full Stop Protection filter, or are available sterile. The RES-Q-VAC currently has greater performance and while lower cost devices initially did affect our sales, currently it appears that we are increasing and maintaining sales in this market. However with the decrease in funding to the emergency medical market due to an economic downturn, there can be no assurance that our sales will continue at the current level, or that these lower cost devices will not begin to erode our markets.

TRADE SHOWS
- ----------

In this quarter ended August 31, 2008, we will be attending tradeshows for Freedom60 including ESID (European Society for Immunodeficiency's) from October 16 to 19 held in the Netherlands and Medica from November 19 to 22 held in Dusseldorf, Germany.

During this quarter we also held numerous training sessions for the subcutaneous administration of Vivaglobin using the Freedom60. These sessions included September 16 to 17 in Tampa, FL, June 1 in Atlanta, GA and another in Hamington, NJ. We also held a session July 7 for a clinic in Cleveland, OH.

September 4 we held new distributor training in Middletown, NY and September 29 we held another training session for a distributor in Finland.

For RES-Q-VAC we will be attending the EMS Expo from October 16 to 19 held in Las Vegas, NV.

PART I ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
- ----------

We currently have a loan in the principal of $400,000 at a favorable interest rate guaranteed by a director which we plan to renegotiate.

PART I ITEM 4. CONTROLS AND PROCEDURES
- ----------

Disclosure Controls and Procedures

As of August 31, 2008, under the supervision and with the participation of the Company's Chief Executive Officer and Financial Officer, management continually evaluates the effectiveness of the design and operation of the our disclosure controls and procedures. Based on our evaluation, we have concluded that the Company's disclosure controls and procedures were effective as of August 31, 2008.

Changes in Internal Control over Financial Reporting

There were no changes in internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to affect, the Company's internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are, from time to time, subject to claims and suits arising in the ordinary course of business, including claims for damages for personal injuries, breach of management contracts and employment related claims.

ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS

None

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

No matters were submitted to a vote of security holders of the Company during the quarter ended August 31, 2008.

ITEM 5. OTHER INFORMATION

None

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

None

SIGNATURES

Pursuant to the requirements of Section 13 or 15 (d) of the Securities Exchange Act of 1934 the Registrant has duly caused this report to be signed on its behalf by the undersigned; thereunto duly authorized.

REPRO-MED SYSTEMS, INC.

/s/ Andrew I. Sealfon October 15, 2008

Andrew I. Sealfon, President, Treasurer,
Chairman of the Board, Director, and
Chief Executive Officer

EXHIBIT 31.1

CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Andrew I. Sealfon, certify that:

1. I have reviewed the Form 10-Q of Repro-Med Systems, Inc. (the "Report") for the quarter ended August 31, 2008.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;

4. The small business issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the small business issuer and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) evaluated the effectiveness of the small business issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(c) disclosed in this report any change in the small business issuer's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer's internal control over financial reporting; and

5. The small business issuer's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer's auditors and the audit committee of the small business issuer's board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer's ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer's internal control over financial reporting.

Date: October 15, 2008

/s/ Andrew I. Sealfon
- ----------
Andrew I. Sealfon, President, Treasurer,
Chairman of the Board, Director, Chief Executive Officer
and Principal Financial Officer

EXHIBIT 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTIONS 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Repro-Med Systems, Inc. (the "Company") on Form 10-Q for the period ending August 31, 2008, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Andrew I. Sealfon, Chief Executive Officer and Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Andrew I. Sealfon
- ----------
Andrew I. Sealfon, President, Treasurer,
Chairman of the Board, Director, Chief Executive Officer
and Principal Financial Officer

October 15, 2008